Scribe Therapeutics Inc.
Scribe Therapeutics Inc.
Your view on SCTX
Overview
What the company does, where it operates, and who runs it.
About Scribe Therapeutics Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Benjamin L. Oakes
- Headquarters
- 1150 MARINA VILLAGE PARKWAY, Alameda, CA, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Benjamin L. Oakes
- Headquarters
- 1150 MARINA VILLAGE PARKWAY, Alameda, CA, US
Scribe Therapeutics is a clinical-stage biotechnology company focused on developing in vivo CRISPR-based genetic medicines.
The company engineers proprietary technologies to target the genetic drivers of disease, with an initial focus on atherosclerotic cardiovascular disease (ASCVD), aiming to shift treatment from chronic care to preventative intervention.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
Fair value for Scribe Therapeutics Inc. from FRC's valuation model, read against the market price. SCTX last traded at $16.99; the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Scribe Therapeutics Inc.. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Scribe Therapeutics Inc.. Scribe Therapeutics Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Scribe Therapeutics Inc.. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
1-Year Price Target
Low
$37.00
Median
$55.00
High
$60.00
Average target · 4 new targets in the last 3 months, average $51.75
Analyst Ratings
- Strong Buy0
- Buy1
- Hold0
- Sell0
- Strong Sell0
Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep; as of Nov 13, 2026. Not FRC research or a recommendation.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Scribe Therapeutics Inc.. Scribe Therapeutics Inc. has reported as a listed company since 2026. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Scribe Therapeutics Inc. valued side by side against its closest peers. Scribe Therapeutics Inc. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Insider Trading
Recent buying and selling by company executives.
Buying and selling by Scribe Therapeutics Inc. executives and directors. Shares of Scribe Therapeutics Inc. have traded between $19.40 and $26.50 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Scribe Therapeutics Inc.. Coverage tracks Scribe Therapeutics Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.
Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Scribe Therapeutics Inc.